Analysts expect Accuray Incorporated (NASDAQ:ARAY) to announce earnings of ($0.06) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Accuray’s earnings. Accuray also reported earnings per share of ($0.06) during the same quarter last year. The business is scheduled to issue its next earnings results on Tuesday, January 22nd.
On average, analysts expect that Accuray will report full-year earnings of ($0.14) per share for the current fiscal year, with EPS estimates ranging from ($0.24) to ($0.02). For the next financial year, analysts anticipate that the company will report earnings of $0.09 per share, with EPS estimates ranging from $0.02 to $0.16. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Accuray.
Accuray (NASDAQ:ARAY) last posted its quarterly earnings results on Tuesday, October 30th. The medical equipment provider reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.02). The company had revenue of $95.83 million during the quarter, compared to analysts’ expectations of $95.10 million. Accuray had a negative return on equity of 42.24% and a negative net margin of 5.79%. During the same period in the prior year, the business earned ($0.11) EPS.
In other Accuray news, CEO Joshua Levine bought 25,000 shares of the business’s stock in a transaction on Monday, November 5th. The shares were acquired at an average price of $4.75 per share, with a total value of $118,750.00. Following the transaction, the chief executive officer now owns 1,356,036 shares of the company’s stock, valued at approximately $6,441,171. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Shigeyuki Hamamatsu sold 8,762 shares of the firm’s stock in a transaction dated Tuesday, October 2nd. The shares were sold at an average price of $4.48, for a total transaction of $39,253.76. Following the completion of the sale, the chief financial officer now owns 116,238 shares in the company, valued at $520,746.24. The disclosure for this sale can be found here. Insiders have sold a total of 48,378 shares of company stock worth $218,502 in the last three months. Insiders own 3.40% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc boosted its holdings in shares of Accuray by 9.6% in the 3rd quarter. Legal & General Group Plc now owns 1,366,100 shares of the medical equipment provider’s stock valued at $6,147,000 after buying an additional 119,149 shares in the last quarter. Putnam Investments LLC bought a new stake in shares of Accuray in the 3rd quarter valued at about $1,337,000. Vident Investment Advisory LLC boosted its holdings in shares of Accuray by 2.3% in the 3rd quarter. Vident Investment Advisory LLC now owns 2,233,056 shares of the medical equipment provider’s stock valued at $10,049,000 after buying an additional 49,156 shares in the last quarter. Paloma Partners Management Co boosted its holdings in shares of Accuray by 754.8% in the 3rd quarter. Paloma Partners Management Co now owns 92,900 shares of the medical equipment provider’s stock valued at $418,000 after buying an additional 82,032 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd boosted its holdings in shares of Accuray by 110.2% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 42,993 shares of the medical equipment provider’s stock valued at $193,000 after buying an additional 22,544 shares in the last quarter. Institutional investors and hedge funds own 85.36% of the company’s stock.
ARAY stock traded down $0.16 during trading on Friday, hitting $4.35. The company had a trading volume of 30,738 shares, compared to its average volume of 971,314. The company has a market capitalization of $390.84 million, a PE ratio of -15.32 and a beta of 1.60. Accuray has a 52-week low of $3.20 and a 52-week high of $6.15. The company has a debt-to-equity ratio of 2.74, a current ratio of 1.69 and a quick ratio of 0.96.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Featured Story: How to Calculate Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.